Posted by Michael Wonder on 26 Jun 2022
argenx receives positive CHMP opinion for efgartigimod for the treatment of adult patients with generalised myasthenia gravis in Europe
24 June 2022 - Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures.
argenx today announced that the CHMP of the EMA has recommended European Commission approval of efgartigimod as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody positive.
